Skip to content

Ticagrelor and platelet reactivity in acute coronary syndromes

Acute Coronary Syndrome patients and the effects of ticagrelor loading dose on level of platelet inhibition

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613001208796
Enrollment
50
Registered
2013-11-04
Start date
2013-12-09
Completion date
2014-06-09
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Following a heart attack we give all patients drugs that act on platelets that circulate in the blood. These drugs, aspirin and ticagrelor, act on the platelets to limit the amount of blood clotting that occurs following the heart attack. The standard amount of ticagrelor we give people initially is 180mg. A study has shown that with this amount of the drug it can take 8 to 12 hours until the full effect of the drug is observed. We want to know if by doubling the initial dose to 360mg we can reduce the time it takes to see the full effects.

Interventions

Randomised, double-blind clinical trial comparing the effects of a single 180mg Ticagrelor loading dose given orally (control) with a single 360mg Ticagrelor loading dose given orally (intervention) on platelet inhibition in patients with acute coronary syndromes. This is the initial treatment, following which patients will undergo angiography. Depending on the findings at angiography patients may be prescribed dual anti platelet therapy (ticagrelor and aspirin) daily for up to 1 year, but this

Randomised, double-blind clinical trial comparing the effects of a single 180mg Ticagrelor loading dose given orally (control) with a single 360mg Ticagrelor loading dose given orally (intervention) on platelet inhibition in patients with acute coronary syndromes. This is the initial treatment, following which patients will undergo angiography. Depending on the findings at angiography patients may be prescribed dual anti platelet therapy (ticagrelor and aspirin) daily for up to 1 year, but this is beyond the scope of this study, which is only investigating the effects of the initial loading dose.

Sponsors

Peter Larsen
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
30 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

Acute coronary syndrome

Exclusion criteria

Known platelet function disorder Platelet count less than 100 Prior administration of a P2Y12 receptor antagonist within 2 weeks

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026